{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-003349","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.912239+00:00","generated_at":"2026-06-18T04:20:52.766535+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix reports FY2022 net loss of $116.9M; cash $120.2M; pipeline milestones ahead","bullets":["Net loss $34.1M in Q4 2022 ($0.56/share) vs $29.6M ($2.08) in Q4 2021; FY net loss $116.9M ($3.27) vs $92.3M ($8.10).","Cash and equivalents $120.2M at Dec 31, 2022, down from $178.7M a year ago; cash used in operations $98.1M in FY2022.","Repurchased 15.7M shares under $12.5M program; new $12.5M program approved Jan 2023 with 1M shares bought.","Interim analysis for Phase 3 fibromyalgia study (TNX-102 SL) expected Q2 2023; topline Q4 2023.","Appointed R. Newcomb Stillwell to Board; acquired antiviral assets from Healion Bio; licensed monoclonal antibodies from Columbia."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-003349","json":"https://secwatch.observer/filing/0001387131-23-003349.json","markdown":"https://secwatch.observer/filing/0001387131-23-003349.md","text":"https://secwatch.observer/filing/0001387131-23-003349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/0001387131-23-003349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/tnxp-8k_031323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:20:52.766535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2b8acb2e88b4b711acc6cd9c1f26bbcb6507fbc","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 13, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/0001387131-23-003349-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}